ziprasidone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 43 Diseases   13 Trials   13 Trials   784 News 


«123456789101112»
  • ||||||||||  amisulpride / Generic mfg., ziprasidone / Generic mfg.
    Journal:  Safety Profile of Antipsychotic Drugs: Analysis Based on a Provincial Spontaneous Reporting Systems Database. (Pubmed Central) -  Apr 1, 2022   
    Statistics showed that low-level hospitals, psychiatric hospitals, youth, and old age were risk factors for serious ADRs. The four off-label signals obtained by signal mining should be paid special attention, including amisulpride-pollakiuria, ziprasidone-dyspnoea, quetiapine-urinary incontinence, and olanzapine-hepatic function abnormal.
  • ||||||||||  ziprasidone / Generic mfg.
    Clinical, Journal:  Neuroleptic Malignant Syndrome: A Potential Etiology of Multisystem Organ Failure in a Burn Patient. (Pubmed Central) -  Feb 25, 2022   
    Upon further investigation, the patient reported taking ziprasidone for his bipolar disorder, and he had a core temperature of 103.5 °F on his initial presentation to the outside facility...We hypothesized that dehydration, the warm environmental conditions at our patient's job, and immense stress resulting in a catecholamine surge following his trauma were inciting triggers to this event. This case highlights the importance of considering alternate diagnoses in patients whose clinical presentation does not fit the most "obvious cause."
  • ||||||||||  olanzapine / Generic mfg., ziprasidone / Generic mfg.
    Enrollment open, HEOR, Cost effectiveness:  Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia (clinicaltrials.gov) -  Feb 24, 2022   
    P1,  N=24, Recruiting, 
    This case highlights the importance of considering alternate diagnoses in patients whose clinical presentation does not fit the most "obvious cause." Suspended --> Recruiting
  • ||||||||||  risperidone / Generic mfg., oxycodone controlled release / Generic mfg., ziprasidone / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Reducing the Abuse of Opioids in Drug Users (clinicaltrials.gov) -  Feb 15, 2022   
    P1,  N=3, Terminated, 
    Suspended --> Recruiting N=25 --> 3 | Trial completion date: Aug 2022 --> Jan 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Mar 2021; PI leaving institution
  • ||||||||||  Rexulti (brexpiprazole) / Lundbeck, Otsuka
    Clinical, Journal:  Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. (Pubmed Central) -  Feb 3, 2022   
    Individually, aripiprazole, olanzapine+fluoxetine, risperidone, and ziprasidone all were more effective (all NNT < 10) than quetiapine (NNT = 13), brexpiprazole (16), or cariprazine (16), with overlapping NNT CIs...Several modern antipsychotics and esketamine appeared to be useful adjuncts to antidepressants for acute major depressive episodes, but lithium was somewhat more effective and better tolerated. Most trials of adding lithium involved older, mainly tricyclic, antidepressants, and the dosing of adjunctive treatments were not optimized.
  • ||||||||||  risperidone / Generic mfg., ziprasidone / Generic mfg., clozapine / Generic mfg.
    Journal:  Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. (Pubmed Central) -  Feb 3, 2022   
    Apparent efficacy of specific agents ranked: risperidone ⩾ olanzapine ⩾ aripiprazole ⩾ ziprasidone ⩾ mixed drugs for psychosis ⩾ quetiapine, but none of these differences was significant. An ability of clozapine to reduce risk of suicides and attempts in schizophrenia patients appears to be a unique effect not shared with other modern medicines indicated for schizophrenia or bipolar disorder.
  • ||||||||||  risperidone / Generic mfg., amisulpride / Generic mfg., ziprasidone / Generic mfg.
    Clinical, Journal:  Factors associated with laxative use in schizophrenia patients treated with second-generation antipsychotics. (Pubmed Central) -  Jan 18, 2022   
    In contrast, sulpiride was least associated with laxative use among all SGAs...Laxative use is common in schizophrenia patients treated with SGAs. For clinically significant constipation, switching to an SGA with a lower risk for constipation, and decreasing the doses of SGAs and anticholinergics should be considered.
  • ||||||||||  risperidone / Generic mfg., oxycodone controlled release / Generic mfg., ziprasidone / Generic mfg.
    Enrollment closed, Trial completion date:  Reducing the Abuse of Opioids in Drug Users (clinicaltrials.gov) -  Jan 11, 2022   
    P1,  N=25, Active, not recruiting, 
    With regards to the general PBPK modeling methodology, modelers should account for the full solubility profile when modeling ionizable compounds, including common ion effects, and apply a straightforward strategy to account for drug precipitation. Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Aug 2022
  • ||||||||||  Rexulti (brexpiprazole) / Lundbeck, Otsuka, Metopirone (metyrapone) / HRA Pharma
    Review, Journal:  Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. (Pubmed Central) -  Jan 7, 2022   
    Studies on lamotrigine and pindolol reported negative results...Reliable conclusions about the other molecules cannot be drawn. Further controlled comparative studies, standardized in terms of design, doses, and duration of the augmentative treatments, are needed to formulate definitive conclusions.
  • ||||||||||  risperidone / Generic mfg., ziprasidone / Generic mfg.
    Can Pediatric Bipolar Disorder Be Successfully Treated When Comorbid With Conduct Disorder? A Secondary Analysis Of Six Clinical Trials Of Second Generation Antipsychotics () -  Dec 18, 2021 - Abstract #AACAP2021AACAP_1166;    
    The antimanic effects observed were almost identical in BP youths with and without comorbid CD, as measured either by a reduction in Young Mania Rating Scale (YMRS) ≥30% or Clinical Global Impression (CGI)-Improvement scale ≤2 (p = 0.23), or by the more stringent definition of a reduction in YMRS ≥50% (p = 0.61).Conclusions Pediatric BP can be effectively treated with SGAs in the context of comorbid CD. Based on previous research showing that remission of BP is associated with remission of CD, if confirmed, these findings raise the possibility that antimanic treatment of youth with BP comorbid with CD could have secondary benefits in mitigating the morbidity associated with CD.BRD, CD
  • ||||||||||  Use Of Metformin To Attenuate Bmi Changes Associated With Second-Generation Antipsychotic Use In The Youth In The Care, Child, And Adolescent Population () -  Dec 18, 2021 - Abstract #AACAP2021AACAP_732;    
    The odds of increasing the BMI z score among patients in the control group were 2.39 times higher than the odds for those in the metformin group (β = 1.243; SE = 0.425; OR = 3.466; 95% CI, 1.32-4.84; p < 0.003). For a 1-point increase in the BMI z score weight difference among youth-in-care in the metformin group, there is a 2.39 increase in the BMI z score weight among youth-in-care in the control group.Conclusions The addition of metformin for patients on a second-generation antipsychotic within the youth-in-care population led to decreased change in BMI z score when compared to their matched subjects.APS, PRE, OBE
  • ||||||||||  ziprasidone / Generic mfg.
    Journal:  Identification of Novel Impurity of Ziprasidone. (Pubmed Central) -  Nov 17, 2021   
    It was isolated from an enriched sample by preparative HPLC, and its structure was elucidated by comprehensive analysis of HRMS, 1D NMR (H, C), DEPT-135, 2D NMR (COSY, HSQC, HMBC) spectroscopy. A plausible mechanism for the formation of isolated impurity is proposed.
  • ||||||||||  risperidone / Generic mfg., ziprasidone / Generic mfg.
    Review, Journal:  Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. (Pubmed Central) -  Oct 30, 2021   
    Pharmacological therapies, such as alpha agonists, topiramate, and vesicular monoamine transport type 2 inhibitors, are generally used as first-line therapies in patients with troublesome tics that are not controlled by behavioral therapy or when the latter is not available or accessible...Second-line therapy includes antipsychotics, such as fluphenazine, aripiprazole, risperidone, and ziprasidone...There is promise in ongoing clinical trials with D1 receptor antagonist ecopipam and other experimental therapeutics. Patients with tics that are refractory to conventional treatments may be candidates for deep brain stimulation, but further studies are needed to determine the optimal target selection.
  • ||||||||||  risperidone / Generic mfg., oxycodone controlled release / Generic mfg., ziprasidone / Generic mfg.
    Trial completion date, Trial primary completion date:  Reducing the Abuse of Opioids in Drug Users (clinicaltrials.gov) -  Oct 25, 2021   
    P1,  N=25, Recruiting, 
    Patients with tics that are refractory to conventional treatments may be candidates for deep brain stimulation, but further studies are needed to determine the optimal target selection. Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  ziprasidone / Generic mfg.
    [VIRTUAL] Acute Interstitial Nephritis Secondary to Cocaine Use () -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_925;    
    She was started on IV methylprednisolone 1 g/daily for 3 days and then switched to oral prednisone 1 mg/kg for 8 weeks. HD was discontinued, urine output improved, with complete renal recovery on outpatient follow up Discussion We believe that AIN must be in the differential when treating patient with AKI and recent cocaine use, treatment must be started as earlier as possible to prevent progression to chronic kidney disease with fibrosis
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
    Clinical, Journal:  Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs. (Pubmed Central) -  Oct 13, 2021   
    Oral first-generation antipsychotics (hazard ratio=1.16), oral risperidone (hazard ratio=1.15), oral aripiprazole (hazard ratio=1.14), oral ziprasidone (hazard ratio=1.13), and oral quetiapine (hazard ratio=1.11) were significantly associated with an increased risk of discontinuation compared with oral olanzapine...In a national sample of veterans with schizophrenia, those treated with clozapine, two of the LAI second-generation antipsychotics, and antipsychotic polypharmacy continued the same antipsychotic therapy for a longer period of time compared with the reference drug. This may reflect greater overall acceptability of these medications in clinical practice.
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Trial completion, HEOR:  Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) -  Oct 7, 2021   
    P=N/A,  N=1037352, Completed, 
    The proposed method also provided a simple, reliable, specific, and suitable technique for TDM and pharmacokinetic studies. Enrolling by invitation --> Completed
  • ||||||||||  amisulpride / Generic mfg., lurasidone / Generic mfg., ziprasidone / Generic mfg.
    Review, Journal:  Amisulpride - is it as all other medicines or is it different? An update. (Pubmed Central) -  Sep 1, 2021   
    In 2018, the Agency for Health Technology Assessment and Tariff System issued positive recommendation for lurasidone in schizophrenia (Recommendation 30/2018) facilitating its entry to the market...It might also be superior to haloperidol in inducing symptomatic remission in first episode schizophrenia...Therefore many patients accept treatment with amisulpride for its measurable clinical gains, such as improvement of positive symptoms and higher quality of life, compared to typical neuroleptics. Pharmacokinetics of amisulpride also encourage its wider use, especially when there is either a need for combined psychopharmacotherapy or comorbidity with general medical condition rises a need for somatic parallel treatment.
  • ||||||||||  Journal:  How to treat mania. (Pubmed Central) -  Aug 20, 2021   
    Despite the evidence forefficacy of many currently available treatments for mania, the majority of RCTs provide little direction for the clinician as to what steps might be optimal in different presentations of mania as well as in the presence of specific patient characteristics. Manic episodes should be managed on a personalized basis considering the clinical course and patient criteria and with the expectation of maintaining that treatment in the long-term.